- Personalis, Inc. (NASDAQ: PSNL) is currently undergoing an acquisition by Tempus AI, Inc. (NASDAQ: TEM), a deal valued at $16.25 per share.
- The acquisition is under investigation by shareholder rights firms, focusing on fairness to Personalis, Inc. shareholders and potential insider benefits.
- Personalis, Inc. is scheduled to report its earnings on August 4, 2026, with analysts forecasting an EPS of -$0.25 and revenues of $16.69 million.
Personalis, Inc. (NASDAQ: PSNL) is a leading precision oncology company that focuses on advanced genomic tests. It is a leader in molecular residual disease (MRD) testing, which helps detect cancer that may remain after treatment. The company is currently being acquired by Tempus AI, Inc. (NASDAQ: TEM), an existing shareholder and strategic partner, impacting the MRD testing market.
On August 4, 2026, Personalis, Inc. is scheduled to report its earnings. Wall Street analysts are anticipating an earnings per share (EPS) of -$0.25. EPS represents the company's profit or loss allocated to each share of stock. Analysts also estimate revenues will be around $16.69 million for the quarter, a key part of their earnings forecast.
These estimates follow a quarter where the company reported total revenue of $15.47 million. After a cost of revenue of $15.19 million, its gross profit was about $281,000. However, the company posted a net loss of $30.03 million, which translates to a loss per share of $0.29, reflecting its recent financial performance analysis.
The acquisition by Tempus AI, Inc. is for a value of $16.25 per share. However, this deal is under investigation by shareholder rights firms like Julie & Holleman LLP and Halper Sadeh LLC. The investigations focus on whether the deal is fair to Personalis, Inc. shareholders and if insiders are receiving special benefits, raising concerns about potential shareholder litigation.
Concerns exist that the terms of the deal may prevent better offers from other companies, as highlighted by GlobeNewsWire. These legal reviews add another layer of complexity for shareholders as Personalis, Inc. prepares to release its next financial report, impacting the overall stock acquisition news.